What's in Immodulon Therapeutics Ltd's pipeline?

Immodulon Therapeutics Ltd has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Immodulon Therapeutics Ltd's portfolio?

Top competitors by shared drug class: CEL-SCI Corporation, Haffkine Bio-Pharmaceutical Corporation Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/immodulon-therapeutics-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Immodulon Therapeutics Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immodulon Therapeutics Ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
IMM-101	IMM-101	phase 3	Cancer immunotherapy vaccine		Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CEL-SCI Corporation · 1 shared drug class
Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Immodulon Therapeutics Ltd:

Cite this brief

Drug Landscape (2026). Immodulon Therapeutics Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/immodulon-therapeutics-ltd. Accessed 2026-06-10.